Optimizing Access in Locally Advanced Non-Small Cell Lung Cancer: Hypofractionated Radiation Therapy as a Resource-Efficient Alternative to Conventional Schedules
文献摘要
Purpose Concomitant chemoradiation therapy (cCRT) is a standard-of-care treatment option for locally advanced non-small cell lung cancer, improving locoregional control (LRC) and overall survival (OS). However, many patients are unfit for cCRT and receive sequential chemoradiation therapy (sCRT); in this setting, hypofractionated radiation therapy may reduce treatment time, counter tumor repopulation, and improve access. Methods and materials We retrospectively analyzed outcomes and prognostic factors among 131 patients with locally advanced non-small cell lung cancer treated at a single high-volume cancer center with 1 of 3 approaches: cCRT with conventional fractionation (CONV-C; n = 52), sCRT with conventional fractionation (CONV-S; n = 37), or sCRT with hypofractionation (HYPO-S; n = 42). Results After a median follow-up of 19.6 months, OS, progression-free survival, and distant failure-free survival were comparable among groups. LRC was significantly higher with HYPO-S (62.0%) than with CONV-S (34.8%; p = .009) and similar to CONV-C (62.0%). In multivariate analysis, LRC with HYPO-S remained comparable to CONV-C ( p = .576), whereas CONV-S was associated with inferior LRC compared with HYPO-S (hazard ratio, 2.257; 95% CI, 1.046-4.867; p = .038). Toxicity profiles were acceptable, with no significant differences in rates of grade ≥2 esophagitis or pneumonitis across groups. Conclusions Sequential hypofractionated chemoradiation therapy achieved LRC and OS comparable to cCRT and superior LRC compared with sequential conventional schedules, without increased toxicity. These findings support broader adoption of HYPO-S as a resource-efficient, clinically effective strategy for patients ineligible for cCRT, particularly in low-income and middle-income health care systems.